Hims & Hers to Sell Lilly’s Zepbound After 35% Stock Surge
Hims & Hers Health stock surged 35% to $21.27 after ending its GLP-1 advertising dispute, paving way for direct transfers to Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. Hims will also begin selling Zepbound on its website, creating a new digital channel that could boost Lilly’s obesity therapy sales.
1. Dispute Resolution Enables Transfers
Hims & Hers Health has agreed to cease advertising its own GLP-1 weight-loss drugs, allowing patients to transfer prescriptions directly to Eli Lilly’s Zepbound or Novo Nordisk’s Wegovy. The settlement resolves a legal dispute and removes promotional barriers for both competitors’ therapies.
2. Zepbound Digital Sales Channel Opens
Under the new agreement, Hims & Hers will begin offering Zepbound on its online platform, providing a direct-to-consumer channel that complements Lilly’s existing distribution network. This digital integration could accelerate patient access and streamline prescription fulfillment.
3. Investor Reaction and Trading Spike
Shares of Hims & Hers surged 35% to $21.27 on heavy volume, marking the largest single-session gain in company history. The spike reflects strong investor confidence in the potential sales upside for partner drugs like Zepbound.
4. Strategic Growth for Lilly’s Obesity Franchise
Expanding Zepbound availability through Hims & Hers enhances Lilly’s reach in the competitive GLP-1 obesity market, potentially driving incremental sales and bolstering market share against Novo Nordisk’s offerings.